BLOG — Covid-19

The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 PatientsPreprints with The Lancet 19 Pages Posted: 7 Feb 2023 Abstract BACKGROUND: Excessive inflammation and lymphopenia are linked to poor Covid-19 clinical outcomes. Targeting both conditions using an immunomodulating approach needs to be tested.METHODS: We conducted an open-label, randomized, controlled trial of MAF Capsules and M Capsules in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection but at enrolment did not require resuscitation or mechanical ventilation. Patients were randomly assigned to receive, in addition to standard of care...

In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment.   In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the...